Price (90d)
No price history yet — the daily price refresh runs once a day.
Signal Score (90d)
90Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $19.65M | $-7.57M | $-0.29 |
| 2024 | $29.58M | $-15.31M | $-0.85 |
| 2023 | $18.06M | $-20.85M | $-1.48 |
| 2022 | $25.37M | $-2.91M | $-0.16 |
| 2021 | $15.24M | $-3.99M | $-0.33 |
Social Signal Score
Earnings
Tue, Nov 10(in 3 months)
Consensus estimate $-0.14 per share
Typical surprise +3.7% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Aug 11$-0.13 vs $-0.14beat
- Tue, May 12$-0.11 vs $-0.11beat
- Tue, Mar 24$-0.11 vs $-0.12beat
- Tue, Nov 11$-0.13 vs $-0.09miss
- Tue, Aug 12$-0.10 vs $-0.07miss
- Wed, May 14$0.11 vs $-0.10beat
Estimates and results for MDAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Valuation
MDAIhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Mentions (2)
- Newsseekingalpha.com·3d ago·Positive
Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·3d ago·Negative
Spectral AI Q2 Earnings Call Highlights Spectral AI NASDAQ: MDAI said its second-quarter results marked a transition toward commercial operations following the U.S. Food and Drug Administration's De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 million, which does not assume significant revenue from DeepView system sales.
View source ↗
